G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D) TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) MODIFIED T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA NCT04555551; Mailankody S PI et al NEJM 2022 Phase I single center study at Memorial Sloan Kettering Cancer Center of MCARH109
A STUDY OF CC-98633, BCMA-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS, IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA NCT04394650; Megala Costa L et al ASH 2022 Multi-center phase I of BCMA-Targeted CARs using NEX-T manufacturing
A STUDY OF CC-95266 IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA NCT04674813; DFCI PI Omar Nadeem et al ASH 2022 Multi-center phase I of GPRC5D-Targeted CARs
GPRC5D ANTIBODY BASED THERAPIES Pre-clinical Being Developed by Sanofi Link here
STUDY EVALUATING THE SAFETY AND EFFICACY OF JCARH125 IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (EVOLVE) NCT03430011; Mailankody S et al ASH 2018a; Mailankody S et al ASCO 2020 Multi-center phase II study of Orvacabtagene autoleucel (formerly JCARH125)
BCMA TARGETED CAR T CELLS WITH OR WITHOUT LENALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA NCT03070327; Mailankody S et al ASH 2018b Phase I single center study at Memorial Sloan Kettering Cancer Center of MCARH171
IMMUNOTHERAPY WITH BCMA CAR-T CELLS IN TREATING PATIENTS WITH BCMA POSITIVE RELAPSED OR REFRACTORY MULTIPLE MYELOMA NCT03338972; Green D et al ASH 2018; Green D et al ASH 2019 Phase I single center study at Fred Hutchinson Cancer Research Center using FCARH143
BCMA-SPECIFIC CAR T-CELLS COMBINED WITH A GAMMA SECRETASE INHIBITOR (JSMD194) TO TREAT RELAPSED OR PERSISTENT MULTIPLE MYELOMA NCT03502577; Cowan A et al ASH 2019 Phase I single center study at Fred Hutchinson Cancer Research Center using FCARH143